In The News,
Lindsay Bealor Greenleaf discusses the administration’s Part B drug International Pricing Index model with Fierce Healthcare
[el-text]
Written by Paige Minemyer
***excerpt***
“Besides the notion of tying drug prices to what’s going on in other countries, the other big issue in today’s announcement is: How is all of this going to impact the independent practices?” Greenleaf said.
***end excerpt***
***
[/el-text]